Management of aminoglycosides in the intensive care unit (Q42908869)

10 November 2017

Management of aminoglycosides in the intensive care unit (English)

1 reference

10 November 2017

1 reference

Elizabeth A Radigan

1

1 reference

10 November 2017

Neil A Gilchrist

series ordinal

2

1 reference

10 November 2017

Melissa A Miller

series ordinal

3

1 reference

10 November 2017

13 September 2010

1 reference

Journal of Intensive Care Medicine

10 November 2017

1 reference

10 November 2017

25

1 reference

10 November 2017

6

1 reference

10 November 2017

327-342

1 reference

National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002.

10 November 2017

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

21 January 2018

Acinetobacter infection

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Cephalosporin use in treatment of patients with penicillin allergies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Aminoglycoside research 1975-1985: prospects for development of improved agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Once-daily dosing of aminoglycosides: review and recommendations for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

An overview of drug-induced acute kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Relationship Between Aminoglycoside-Induced Nephrotoxicity and Auditory Toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Reduction of experimental gentamicin nephrotoxicity in rats by dietary calcium loading

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Protective effects of vitamin e and probucol against gentamicin-induced nephrotoxicity in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Protection from Gentamicin Nephrotoxicity by Cephalothin and Carbenicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Ceftriaxone protects against tobramycin nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Experience with a once-daily aminoglycoside program administered to 2,184 adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Genetic factors in aminoglycoside toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Inherited susceptibility to aminoglycoside ototoxicity: genetic heterogeneity and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Aminoglycoside-induced hearing loss in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Risk factors for the development of auditory toxicity in patients receiving aminoglycosides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Aspirin to prevent gentamicin-induced hearing loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Deafness and prolonged neuromuscular blockade following single-dose peritoneal neomycin irrigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Tobramycin-Curare Interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Comparison of gentamicin dosing regimens using an in-vitro model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Aminoglycoside nephrotoxicity: do time and frequency of administration matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Effect of once-daily dosing vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Experience with a once-daily dosing program of aminoglycosides in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Evaluation of four once-daily aminoglycoside dosing nomograms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Pharmacokinetic changes in critical illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Pharmacokinetics of drugs used in critically ill adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Validation of the Hartford nomogram in trauma surgery patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Clinical predictors of subtherapeutic aminoglycoside levels in trauma patients undergoing once-daily dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Critical care of the bariatric patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Aminoglycoside dosing weight correction factors for patients of various body sizes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Characterization of gentamicin pharmacokinetics in patients hemodialyzed with high-flux polysulfone membranes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

The impact of critical care pharmacists on enhancing patient outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Combination therapy as a tool to prevent emergence of bacterial resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Predicting the efficacy of antimicrobial agents in respiratory infections--is tissue concentration a valid measure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. VAP Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin/tazobactam Nosocomial Pneumonia Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired gram-negative infections. Antibiotic Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Antibiotic treatment of experimental Pseudomonas aeruginosa pneumonia in guinea pigs: comparison of aerosol and systemic administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Acute renal failure associated with inhaled tobramycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Toxic serum trough concentrations after administration of nebulized tobramycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Pharmacokinetics of high-dose nebulized amikacin in mechanically ventilated healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Intensive care unit-acquired urinary tract infections in a regional critical care system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Practice guidelines for the management of bacterial meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Pharmacokinetics and pharmacodynamics of antibiotics in meningitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Amikacin and colistin for treatment of Acinetobacter baumannii meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Intrathecal administration of amikacin for treatment of meningitis secondary to cephalosporin-resistant Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Once-daily versus thrice-daily dosing of netilmicin in combination with beta-lactam antibiotics as empirical therapy for febrile neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Aminoglycosides for intra-abdominal infection: equal to the challenge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Prosthetic-joint infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Aminoglycoside-induced ototoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

Effect of Obesity on Gentamicin Pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066610377968

21 January 2018

Identifiers

DOI

10.1177/0885066610377968

1 reference

release_xeabjobglfc4vc2gu75gpt45sa

10 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xeabjobglfc4vc2gu75gpt45sa

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference